In this captivating podcast series, we dive deep into the world of computational antibody discovery with Ben Holland, our Co-Founder and CTO at Antiverse. Join us as we uncover the immense potential of merging computational and experimental techniques in the pursuit of revolutionary antibodies, as Ben sheds light on the strong benefits and formidable challenges encountered when targeting complex molecules such as GPCRs. With an emphasis on precision and accuracy in predicting antibody-antigen interactions, Ben shares remarkable insights and breakthroughs achieved by computational discovery techniques. Tune in and join us at the forefront of antibody discovery!
Antiverse was co-founded in 2017 with the goal of engineering the future of drug discovery to change people's lives. Based in Cardiff, Antiverse combines machine learning and phage display techniques to model antibody-antigen interactions. The current version of the platform uses next-generation sequencing and AI to design diverse antibody candidates for any given target. The technology is being developed to enable the discovery of biologics for difficult-to-drug targets associated with cancer, heart, and lung diseases.
Podden och tillhörande omslagsbild på den här sidan tillhör Murat Tunaboylu. Innehållet i podden är skapat av Murat Tunaboylu och inte av, eller tillsammans med, Poddtoppen.
